Medicare to Cover PET Scans for Six Types of Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

WASHINGTON-Medicare will soon cover or expand its coverage of the use of positron emission tomography (PET) for the primary diagnosis, staging, or restaging of six types of cancer. The Health Care Financing Administration (HCFA) said it would announce an effective coverage date shortly.

WASHINGTON—Medicare will soon cover or expand its coverage of the use of positron emission tomography (PET) for the primary diagnosis, staging, or restaging of six types of cancer. The Health Care Financing Administration (HCFA) said it would announce an effective coverage date shortly.

The decision covers the use of dedicated full circular ring PET scanners and some partial ring systems for six types of cancer—lung, colorectal, lymphoma, melanoma, esophageal, and head and neck.

HCFA said it will refer the question of PET reimbursement for breast cancer to the Medicare Coverage Advisory Committee, a panel of experts from outside of government that advises the agency on coverage issues.

HCFA’s decision followed a petition filed last summer by UCLA requesting that Medicare cover use of PET in diagnosing 20 types of cancer as well as cardiac and neurologic applications. HCFA then began an evaluation to determine whether current scientific evidence supports the use of PET scans as a "reasonable and necessary" diagnostic procedure for the applications.

The 14 cancers not included in the new decision, including brain and thyroid cancer, will remain uncovered. However, HCFA invited formal requests for new or broader PET coverage for specific cancers.

Until now, Medicare covered only specific uses of PET, such as the localization of a recurrence for a cancer. The new policy provides coverage for all clinically appropriate uses of PET for six cancer types. This means broader coverage for four previously covered cancers and new coverage for two others.

As an example, the agency cited its previous policy of covering PET scans for only one narrow indication for colorectal cancer—the recurrence of colon cancer as evidenced by a rising carcinoembryonic antigen level.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content